Ascendis Pharma A/S – NASDAQ:ASND

Ascendis Pharma A/S stock price today

$194.62
+57.12
+41.54%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ascendis Pharma A/S stock price monthly change

-0.42%
month

Ascendis Pharma A/S stock price quarterly change

-0.42%
quarter

Ascendis Pharma A/S stock price yearly change

+8.18%
year

Ascendis Pharma A/S key metrics

Market Cap
8.21B
Enterprise value
4.54B
P/E
-7.11
EV/Sales
88.72
EV/EBITDA
-9.31
Price/Sales
74.35
Price/Book
14.44
PEG ratio
0.14
EPS
-8.87
Revenue
329.02M
EBITDA
-354.77M
Income
-501.56M
Revenue Q/Q
185.49%
Revenue Y/Y
322.17%
Profit margin
-1139.62%
Oper. margin
-1097.85%
Gross margin
76.28%
EBIT margin
-1097.85%
EBITDA margin
-107.83%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ascendis Pharma A/S stock price history

Ascendis Pharma A/S stock forecast

Ascendis Pharma A/S financial statements

Ascendis Pharma A/S (NASDAQ:ASND): Profit margin
Jun 2023 47.39M -121.43M -256.23%
Sep 2023 48.03M -162.22M -337.73%
Dec 2023 137.70M -86.87M -63.09%
Mar 2024 95.89M -131.03M -136.65%
Ascendis Pharma A/S (NASDAQ:ASND): Analyst Estimates
Dec 2023 137.70M -86.87M -63.09%
Mar 2024 95.89M -131.03M -136.65%
Sep 2025 202.65M 7.23M 3.57%
Dec 2025 235.41M 18.91M 8.03%
  • Analysts Price target

  • Financials & Ratios estimates

Ascendis Pharma A/S (NASDAQ:ASND): Debt to assets
Jun 2023 823823000 758.98M 92.13%
Sep 2023 873213000 946.64M 108.41%
Dec 2023 825587000 971.28M 117.65%
Mar 2024 802504000 1.04B 129.68%
Ascendis Pharma A/S (NASDAQ:ASND): Cash Flow
Jun 2023 -153.12M 46.95M -2.30M
Sep 2023 -124.71M 22.22M 143.35M
Dec 2023 -42.47M 6.65M -6.05M
Mar 2024 -101.58M 7.15M 18.42M

Ascendis Pharma A/S alternative data

Ascendis Pharma A/S (NASDAQ:ASND): Employee count
Aug 2023 797
Sep 2023 797
Oct 2023 797
Nov 2023 797
Dec 2023 797
Jan 2024 797
Feb 2024 797
Mar 2024 879
Apr 2024 879
May 2024 879
Jun 2024 879
Jul 2024 879

Ascendis Pharma A/S other data

100.00% 0.00%
of ASND is owned by hedge funds
61.95M +3.58M
shares is hold by hedge funds
Patent
Application
Filling date: 10 May 2022 Issue date: 25 Aug 2022
Grant
Filling date: 29 Dec 2016 Issue date: 7 Jun 2022
Application
Filling date: 17 Nov 2021 Issue date: 19 May 2022
Grant
Filling date: 25 May 2016 Issue date: 12 Apr 2022
Grant
Filling date: 29 Dec 2016 Issue date: 23 Nov 2021
Application
Filling date: 25 Sep 2019 Issue date: 4 Nov 2021
Application
Filling date: 25 Sep 2019 Issue date: 28 Oct 2021
Application
Filling date: 25 Sep 2019 Issue date: 28 Oct 2021
Grant
Filling date: 16 Apr 2014 Issue date: 14 Sep 2021
Grant
Filling date: 8 Oct 2013 Issue date: 20 Apr 2021
Thursday, 19 December 2024
globenewswire.com
Monday, 16 December 2024
globenewswire.com
Thursday, 12 December 2024
globenewswire.com
Tuesday, 10 December 2024
globenewswire.com
Thursday, 14 November 2024
seekingalpha.com
globenewswire.com
Monday, 30 September 2024
globenewswire.com
globenewswire.com
accesswire.com
Thursday, 19 September 2024
globenewswire.com
Wednesday, 18 September 2024
globenewswire.com
Tuesday, 17 September 2024
zacks.com
zacks.com
Monday, 16 September 2024
benzinga.com
globenewswire.com
Friday, 13 September 2024
globenewswire.com
Wednesday, 11 September 2024
globenewswire.com
Monday, 24 June 2024
globenewswire.com
Tuesday, 4 June 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Wednesday, 15 May 2024
Zacks Investment Research
Tuesday, 14 May 2024
Reuters
Saturday, 4 May 2024
Seeking Alpha
Thursday, 25 April 2024
GlobeNewsWire
Wednesday, 24 April 2024
Zacks Investment Research
Wednesday, 10 April 2024
Market Watch
Friday, 8 March 2024
Zacks Investment Research
Thursday, 15 February 2024
Zacks Investment Research
Zacks Investment Research
  • What's the price of Ascendis Pharma A/S stock today?

    One share of Ascendis Pharma A/S stock can currently be purchased for approximately $194.62.

  • When is Ascendis Pharma A/S's next earnings date?

    Unfortunately, Ascendis Pharma A/S's (ASND) next earnings date is currently unknown.

  • Does Ascendis Pharma A/S pay dividends?

    No, Ascendis Pharma A/S does not pay dividends.

  • How much money does Ascendis Pharma A/S make?

    Ascendis Pharma A/S has a market capitalization of 8.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 421.2% to 266.72M US dollars.

  • What is Ascendis Pharma A/S's stock symbol?

    Ascendis Pharma A/S is traded on the NASDAQ under the ticker symbol "ASND".

  • What is Ascendis Pharma A/S's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Ascendis Pharma A/S?

    Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Ascendis Pharma A/S's key executives?

    Ascendis Pharma A/S's management team includes the following people:

    • Dr. Birgitte Volck M.D., Ph.D. Senior Vice President and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs(age: 63, pay: $42,870)
  • How many employees does Ascendis Pharma A/S have?

    As Jul 2024, Ascendis Pharma A/S employs 879 workers.

  • When Ascendis Pharma A/S went public?

    Ascendis Pharma A/S is publicly traded company for more then 10 years since IPO on 28 Jan 2015.

  • What is Ascendis Pharma A/S's official website?

    The official website for Ascendis Pharma A/S is ascendispharma.com.

  • How can i contact Ascendis Pharma A/S?

    Ascendis Pharma A/S can be reached via phone at +45 70 22 22 44.

Ascendis Pharma A/S company profile:

Ascendis Pharma A/S

ascendispharma.com
Exchange:

NASDAQ

Full time employees:

879

Industry:

Biotechnology

Sector:

Healthcare

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 Ăź/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Tuborg Boulevard 12
Hellerup, 2900

CIK: 0001612042
ISIN: US04351P1012
CUSIP: 04351P101